LeaderPortfolio
Huijuan
Zhong Huijuan
Rank #185
CHINAHealthcarePharmaceuticals

Zhong Huijuan

Net Worth
$15.706B
+2.2% (24h)
Zhong Huijuan, a prominent figure in the pharmaceutical industry, is the founder, CEO, and chair of Hansoh Pharmaceutical Group. Born in 1961, she holds a Bachelor of Science degree from Jiangsu Normal University and an EMBA from Nanjing University. Before her entrepreneurial journey, she was a chemistry teacher. Her career shift in 1995 to establish Hansoh Pharmaceutical, with a focus on oncology, CNS diseases, and metabolic disorders, propelled her to become one of the wealthiest self-made women globally. With a net worth of $18.4 billion, she has demonstrated a commitment to innovation, evidenced by substantial investments in research and development, solidifying her as a leader in the healthcare sector.

How to read Zhong Huijuan's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Zhong Huijuan, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $15.706B alongside global rank #185, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (CHINA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Zhong Huijuan was born in April 1961, in Lianyungang, Jiangsu Province, China. She earned a Bachelor's degree in Chemistry from Jiangsu Normal University in July 1982. After graduating, she started her career as a chemistry teacher at Yan'an Middle School in Lianyungang.

Rise to Success

In 1995, Zhong transitioned from teaching to entrepreneurship. She founded Hansoh Pharmaceutical Group with a team of just ten employees. The company focused on research, development, manufacturing, and sales of drugs for various diseases, including cancer, infectious diseases, and diabetes. Under her leadership, the company invested heavily in research and development. In 1997, the company reached $4.5 million in revenue, which has been growing ever since. In June 2019, Hansoh Pharmaceutical had its initial public offering on the Hong Kong Stock Exchange, raising approximately $1 billion. This significantly increased her wealth and solidified her position in the pharmaceutical industry.

Key Business Strategies

Zhong Huijuan's success is attributed to several key strategies. A primary focus has been on innovation, with Hansoh investing a significant portion of its revenue into research and development. The company also secured licensing deals with global pharmaceutical giants such as Roche, Merck, and GSK, for co-developing drugs. Moreover, Zhong has a long-term vision, committing to sustainable growth, and building a lasting competitive advantage through innovation. The company has a robust pipeline of drugs, with several innovative drugs already generating sales revenue.

Philanthropy

Zhong Huijuan's philanthropy is not extensively detailed in the search results. However, as a leader, she integrates ESG principles with the company's long-term strategy, maintaining an AA rating in the MSCI ESG rating and achieving industry-leading standards in corporate behavior and governance.

Career Timeline

2019

Hansoh Pharmaceutical IPO

Hansoh Pharmaceutical went public on the Hong Kong Stock Exchange, raising approximately $1 billion.

1995

Founded Hansoh Pharmaceutical Group

Transitioned from a chemistry teacher to an entrepreneur by founding Hansoh Pharmaceutical Group.

1982

Graduated from Jiangsu Normal University

Obtained a degree in chemistry.

Philanthropic Impact

Corporate Social ResponsibilityUndisclosed

Not publicly specified

Hansoh integrates ESG principles into its long-term strategy, maintaining an AA rating in the MSCI ESG rating.

Key Business Ventures & Holdings

CompanyStakeValue
Hansoh Pharmaceutical Group66.00%$15.18M

Net Worth History

In-Depth Analysis

Early Life

Zhong Huijuan was born in April 1961, in Lianyungang, Jiangsu Province, China. She earned a Bachelor's degree in Chemistry from Jiangsu Normal University in July 1982. After graduating, she started her career as a chemistry teacher at Yan'an Middle School in Lianyungang.

Rise to Success

In 1995, Zhong transitioned from teaching to entrepreneurship. She founded Hansoh Pharmaceutical Group with a team of just ten employees. The company focused on research, development, manufacturing, and sales of drugs for various diseases, including cancer, infectious diseases, and diabetes. Under her leadership, the company invested heavily in research and development. In 1997, the company reached $4.5 million in revenue, which has been growing ever since. In June 2019, Hansoh Pharmaceutical had its initial public offering on the Hong Kong Stock Exchange, raising approximately $1 billion. This significantly increased her wealth and solidified her position in the pharmaceutical industry.

Key Business Strategies

Zhong Huijuan's success is attributed to several key strategies. A primary focus has been on innovation, with Hansoh investing a significant portion of its revenue into research and development. The company also secured licensing deals with global pharmaceutical giants such as Roche, Merck, and GSK, for co-developing drugs. Moreover, Zhong has a long-term vision, committing to sustainable growth, and building a lasting competitive advantage through innovation. The company has a robust pipeline of drugs, with several innovative drugs already generating sales revenue.

Philanthropy

Zhong Huijuan's philanthropy is not extensively detailed in the search results. However, as a leader, she integrates ESG principles with the company's long-term strategy, maintaining an AA rating in the MSCI ESG rating and achieving industry-leading standards in corporate behavior and governance.

Data Sources & Methodology

Figures for Zhong Huijuan are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.